The Expression of TP63 as a Biomarker of Early Recurrence in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy

Esophageal cancer ranks among the ten most common cancers worldwide. Despite the adoption of neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by surgery as the standard treatment approach in recent years, the local recurrence rate remains high. In this study, we employed RNA-seq to investig...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2024-05, Vol.12 (5), p.1101
Main Authors: Lin, Chih-Hung, Cheng, Po-Liang, Chuang, Cheng-Yeh, Kang, Yu-Ting, Lee, Li-Wen, Hsiao, Tzu-Hung, Hsu, Chung-Ping
Format: Article
Language:English
Subjects:
Biobanks
Biomarkers
Cancer
Cancer therapies
Care and treatment
Chemoradiotherapy
Diagnosis
Epidermis
Esophageal cancer
Esophageal carcinoma
esophageal squamous cell carcinoma
Esophagus
Gene expression
Genes
Immunohistochemistry
Medical prognosis
neoadjuvant concurrent chemoradiotherapy
Oncology, Experimental
Principal components analysis
recurrence
RNA
RNA sequence
Squamous cell carcinoma
Surgery
TP63
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Esophageal cancer ranks among the ten most common cancers worldwide. Despite the adoption of neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by surgery as the standard treatment approach in recent years, the local recurrence rate remains high. In this study, we employed RNA-seq to investigate distinctive gene expression profiles in esophageal squamous cell carcinoma (ESCC) with or without recurrence following a standard treatment course. Our findings indicate that recurrent ESCC exhibits heightened keratinizing and epidermis development activity compared to non-recurrent ESCC. We identified TP63 as a potential candidate for distinguishing clinical outcomes. Furthermore, immunohistochemistry confirmed the trend of TP63 overexpression in ESCC recurrence. Patients with elevated TP63 expression had poorer overall survival and lower 3-year recurrence-free survival. This study underscores the potential of TP63 as a biomarker for detecting cancer recurrence and suggests its role in guiding future treatment options.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines12051101